Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL®)

Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL®)

Pneumococcal conjugate vaccines (PCVs) have proven to be the best way to prevent severe childhood pneumococcal disease but until recently have been difficult for many countries to afford sustainably. In 2008, the Serum Institute of India, Pvt. Ltd. and PATH entered into a collaboration, funded in pa...

Full description

Bibliographic Details
Main Authors: Mark R. Alderson, Vistasp Sethna, Lauren C. Newhouse, Steve Lamola, Rajeev Dhere
Format: Article
Language:English
Published: Taylor & Francis Group 2021-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
pneumococcus
pneumococcal conjugate vaccine
vaccine development
low- and middle-income countries
collaboration
siipl
path
Online Access:http://dx.doi.org/10.1080/21645515.2021.1874219

Similar Items

Similar Items